NOGGIN active protein

Recombinant Human NOGGIN (rHu NOGGIN)

Cat. Num. AAA546127

• Gene Names: NOG; SYM1; SYNS1
• Purity: >95% by SDS-PAGE and HPLC analyses
• Synonyms: NOGGIN; Recombinant Human NOGGIN (rHu NOGGIN); human NOGGIN; Human NOGGIN; NOGGIN active protein

• Host: E. Coli
• Purity/Purification: >95% by SDS-PAGE and HPLC analyses
• Form/Format: Lyophilized from a 0.2~m filtered concentrated solution in 30% acetonitrile, 0.1 % TFA.; Physical Appearance: Sterile Filtered White lyophilized (freeze-dried) powder.
• Sequence: MQHYLHIRPAPSDNLPL VDLIEHPDPIFDPKEKDLNETLLRSLLGGHYDPGF MATSPPEDRPGGGGGAAGGAEDLAELDQLLRQRPSGAMPSEIKGLEFSEGL AQGKKQRLSKKLRRKLQMWLWSQTFCPYLYAWNDLGSFWPRYVKVGSCF SKRSCSVPEGMVCKPSKSVHLTVLRWRCQRRGGQRCG WTPIQYPIIS ECKCSC
• Sequence Length: 232

• Molecular Weight Information: Approximately 46.2 kDa, a single glycosylated polypeptide chain containing 235 amino acids.
• Reconstitution: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in 10mM HAc to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at -20 degree C. Further dilutions should be made in appropriate buffered solutions.
• Biological Activity: The ED50 was determined by its ability to inhibit 5.0 ng/ml of BMP-4 induced alkaline phosphatase production by ATDC-5 chondrogenic cells. The expected ED50 for this effect is 0.05-0.08 ìg/ml of NOGGIN.
• Endotoxin Level: Less than 1EU/mg of rHu NOGGIN as determined by LAL method.
• Usage: This material is offered by MyBioSource Inc. for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE.
• Preparation and Storage: This lyophilized preparation is stable at 2-8 degree C, but should be kept at -20 degree C for longterm storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 degree C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 degree C to -70 degree C. Avoid repeated freeze/thaw cycles.

Related Product Information for NOGGIN active protein

Noggin belongs to a group of diffusible proteins which bind to ligands of the TGF- family and regulate their activity by inhibiting their access to signaling receptors. Noggin was originally identified as a BMP-4 antagonist whose action is critical for proper formation of the head and other dorsal structures. Consequently, Noggin has been shown to modulate the activities of other BMPs including BMP-2,-7,-13, and -14. Targeted deletion of Noggin in mice results in prenatal death and recessive phenotype displaying a severely malformed skeletal system. Conversely, transgenic mice over-expressing Noggin in mature osteoblasts display impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis.

NCBI and Uniprot Product Information

• NCBI GI #: 4885523
• NCBI GeneID: 9241
• NCBI Accession #: NP_005441.1
• NCBI GenBank Nucleotide #: NM_005450.4
• UniProt Accession #: Q13253
• NCBI Official Full Name: noggin
• NCBI Official Synonym Full Names: noggin
• NCBI Official Symbol: NOG
• NCBI Official Synonym Symbols: SYM1; SYNS1
• NCBI Protein Information: noggin; symphalangism 1 (proximal)
• UniProt Protein Name: Noggin
• Protein Family: Noggin
• UniProt Gene Name: NOG
• UniProt Entry Name: NOGG_HUMAN

NCBI Description

The secreted polypeptide, encoded by this gene, binds and inactivates members of the transforming growth factor-beta (TGF-beta) superfamily signaling proteins, such as bone morphogenetic protein-4 (BMP4). By diffusing through extracellular matrices more efficiently than members of the TGF-beta superfamily, this protein may have a principal role in creating morphogenic gradients. The protein appears to have pleiotropic effect, both early in development as well as in later stages. It was originally isolated from Xenopus based on its ability to restore normal dorsal-ventral body axis in embryos that had been artificially ventralized by UV treatment. The results of the mouse knockout of the ortholog suggest that it is involved in numerous developmental processes, such as neural tube fusion and joint formation. Recently, several dominant human NOG mutations in unrelated families with proximal symphalangism (SYM1) and multiple synostoses syndrome (SYNS1) were identified; both SYM1 and SYNS1 have multiple joint fusion as their principal feature, and map to the same region (17q22) as this gene. All of these mutations altered evolutionarily conserved amino acid residues. The amino acid sequence of this human gene is highly homologous to that of Xenopus, rat and mouse. [provided by RefSeq, Jul 2008]

Uniprot Description

NOG: Essential for cartilage morphogenesis and joint formation. Inhibitor of bone morphogenetic proteins (BMP) signaling which is required for growth and patterning of the neural tube and somite. Defects in NOG are a cause of symphalangism proximal syndrome (SYM1). SYM1 is characterized by the hereditary absence of the proximal interphalangeal (PIP) joints (Cushing symphalangism). Severity of PIP joint involvement diminishes towards the radial side. Distal interphalangeal joints are less frequently involved and metacarpophalangeal joints are rarely affected whereas carpal bone malformation and fusion are common. In the lower extremities, tarsal bone coalition is common. Conducive hearing loss is seen and is due to fusion of the stapes to the petrous part of the temporal bone. Defects in NOG are the cause of multiple synostoses syndrome type 1 (SYNS1); also known as synostoses, multiple, with brachydactyly/symphalangism-brachydactyly syndrome. SYNS1 is characterized by tubular-shaped (hemicylindrical) nose with lack of alar flare, otosclerotic deafness, and multiple progressive joint fusions commencing in the hand. The joint fusions are progressive, commencing in the fifth proximal interphalangeal joint in early childhood (or at birth in some individuals) and progressing in an ulnar-to-radial and proximal- to-distal direction. With increasing age, ankylosis of other joints, including the cervical vertebrae, hips, and humeroradial joints, develop. Defects in NOG are the cause of tarsal-carpal coalition syndrome (TCC). TCC is an autosomal dominant disorder characterized by fusion of the carpals, tarsals and phalanges, short first metacarpals causing brachydactyly, and humeroradial fusion. TCC is allelic to SYM1, and different mutations in NOG can result in either TCC or SYM1 in different families. Defects in NOG are a cause of stapes ankylosis with broad thumb and toes (SABTS); also known as Teunissen- Cremers syndrome. SABTS is a congenital autosomal dominant disorder that includes hyperopia, a hemicylindrical nose, broad thumbs, great toes, and other minor skeletal anomalies but lacked carpal and tarsal fusion and symphalangism. Defects in NOG are the cause of brachydactyly type B2 (BDB2). BDB2 is a subtype of brachydactyly characterized by hypoplasia/aplasia of distal phalanges in combination with distal symphalangism, fusion of carpal/tarsal bones, and partial cutaneous syndactyly. Belongs to the noggin family.

Protein type: Secreted; Secreted, signal peptide

Chromosomal Location of Human Ortholog: 17q22

Cellular Component: extracellular space; extracellular region

Molecular Function: protein binding; protein homodimerization activity; cytokine binding

Biological Process: limb development; wound healing; somatic stem cell maintenance; embryonic skeletal development; motor axon guidance; negative regulation of transcription from RNA polymerase II promoter; middle ear morphogenesis; negative regulation of BMP signaling pathway; BMP signaling pathway; notochord morphogenesis; cell differentiation in hindbrain; negative regulation of cardiac muscle cell proliferation; axial mesoderm development; negative regulation of osteoblast differentiation; negative regulation of cell migration; skeletal development; nervous system development; neural plate morphogenesis; in utero embryonic development; osteoblast differentiation; mesoderm formation; dorsal/ventral pattern formation; spinal cord development; pituitary gland development; endoderm formation; cartilage development; neural tube closure; negative regulation of astrocyte differentiation; epithelial to mesenchymal transition; positive regulation of transcription from RNA polymerase II promoter; embryonic digit morphogenesis; positive regulation of epithelial cell proliferation

Disease: Stapes Ankylosis With Broad Thumb And Toes; Symphalangism, Proximal, 1a; Brachydactyly, Type B2; Multiple Synostoses Syndrome 1; Tarsal-carpal Coalition Syndrome